Business Context and Reporting Period
Company: CURIS, INC.
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2009
Business Overview: Curis is a drug discovery and development company focused on targeted cancer therapies. Its primary revenue source is a collaboration with Genentech regarding the Hedgehog pathway inhibitor GDC-0449. The company also maintains an internal pipeline, including CUDC-101 (Phase I) and CUDC-305 (preclinical). Curis has never been profitable and operates with a significant accumulated deficit.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2009 | Six Months Ended June 30, 2008 |
|---|---|---|
| Total Revenues | $6,100,390 | $5,175,393 |
| Net Loss | $(3,056,327) | $(5,395,223) |
| Loss Per Share (Basic & Diluted) | $(0.05) | $(0.09) |
| Research & Development Expenses | $5,197,126 | $6,676,495 |
| General & Administrative Expenses | $4,124,928 | $4,540,303 |
| Cash Used in Operating Activities | $(2,060,504) | $(7,182,282) |
| Cash and Cash Equivalents (End of Period) | $6,465,922 | $9,298,426 |
| Marketable Securities | $20,374,274 | $18,694,200 |
| Total Liquidity (Cash + Marketable Securities) | $26,840,196 | $27,992,626 |
| Accumulated Deficit | $(711,027,163) | $(707,970,836) |
Material Changes vs. Prior Period
- Revenue Composition: Total revenue increased 18% year-over-year, driven entirely by a $6.0 million license fee from Genentech for achieving clinical development milestones. This contrasts with the prior year, which included $1.75 million in license fees from the sale of bone morphogenetic protein assets to Stryker (completed in Q1 2008) and $3.0 million from Genentech. Research and development contract revenue decreased significantly as funding from the Wyeth collaboration concluded in 2008.
- Expense Reductions: Total operating expenses decreased. R&D expenses dropped 22% due to cost-cutting measures, reduced spending on the CUDC-101 program (post-IND filing costs), and the conclusion of the Wyeth program. G&A expenses decreased 9%, primarily due to lower personnel costs and stock-based compensation, partially offset by a 79% increase in legal services related to foreign patent applications.
- Cash Flow Improvement: Net cash used in operating activities improved significantly, decreasing from $7.2 million in the prior year to $2.1 million, reflecting the lower net loss and reduced burn rate.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management anticipates that existing capital resources ($26.8 million as of June 30, 2009) combined with $2.7 million in proceeds from a warrant exercise in July 2009 will fund operations into the fourth quarter of 2010.
- Future Revenue: The company expects no product sales revenue for several years. Future cash flows depend on contingent payments from Genentech, new collaboration agreements (specifically for CUDC-305), and potential royalties.
- Development Milestones:
- GDC-0449 (Genentech): Pivotal Phase II trial in advanced basal cell carcinoma is ongoing; Roche expects to file for regulatory approval in 2011 pending positive results. Phase II trials in colorectal and ovarian cancer are also ongoing.
- CUDC-101 (Internal): Phase I dose escalation trial is ongoing; maximum tolerated dose expected in H2 2009.
- CUDC-305 (Internal): Preclinical development is underway; an IND filing is targeted for Q3 2009. The company is actively seeking a collaborator for this asset.
- Risks:
- Financing: The company will require substantial additional capital beyond late 2010. Failure to secure funding could force the curtailment of development programs.
- Collaboration Dependence: Success is heavily reliant on Genentech's execution of clinical trials for GDC-0449. Genentech has discretion over resource allocation and may terminate the collaboration.
- Market Risk: The company holds significant marketable securities; further deterioration in credit markets could impact the value of these assets.
- Stock Listing: The company faces potential delisting risks from NASDAQ if the stock price remains below the $1.00 minimum bid price requirement (rules suspended temporarily but scheduled to resume August 3, 2009).
Investor Verification Checklist
- Runway Confirmation: Verify the sufficiency of the $29.5 million total liquidity (cash, securities, and July warrant proceeds) to sustain operations through Q4 2010 given the projected increase in R&D costs for CUDC-101 and CUDC-305.
- Genentech Milestone Timing: Monitor the status of the GDC-0449 pivotal Phase II trial in basal cell carcinoma, as future non-dilutive capital is contingent on Genentech achieving regulatory objectives.
- CUDC-305 Collaboration: Assess the progress of discussions to license or collaborate on CUDC-305, as internal funding for its IND filing and subsequent trials may be insufficient without a partner.
- Stock Price Compliance: Track the trading price relative to the $1.00 NASDAQ minimum bid requirement to evaluate delisting risk.
- Legal Expense Volatility: Review the trend in legal services expenses, which increased significantly in the current period due to foreign patent filings, to understand future G&A cost structures.